Impact of Sofosbuvir/Daclatasvir treatment on glycemic control and lipid profile in diabetic patients with chronic hepatitis C

Abstract Background and aim Limited data on the effects of direct-acting antiviral (DAA) drugs on glycemic control and lipid profiles in chronic hepatitis C (CHC) patients with type 2 diabetes mellitus (T2DM). Methods One hundred fifty-one treatment-naïve CHC patients with T2DM, not on insulin and w...

Full description

Bibliographic Details
Published in:	Egyptian Liver Journal
Main Authors:	Tamer Fouad, Ahmed Abd Elraouf, Hassan Elshenawy, Gamal Badra, Heba Abd Allah, Ahmed Attia
Format:	Article
Language:	English
Published:	SpringerOpen 2025-07-01
Subjects:	DAAs Sofosbuvir Daclatasvir Hepatitis C HOMA-IR HbA1C
Online Access:	https://doi.org/10.1186/s43066-025-00436-w

Similar Items

Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease
by: Ahmed Moustafa, et al.
Published: (2024-09-01)

Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia
by: Andri Sanityoso Sulaiman, et al.
Published: (2023-12-01)

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region
by: Fahad Alghamdi, et al.
Published: (2024-06-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir
by: Islam Shah, et al.
Published: (2023-07-01)

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
by: Syed Hassan Murtaza, et al.
Published: (2024-03-01)

Biochemical and Demographic Factors Affecting Antiviral Treatment Failure in Hepatitis C Patients with Persistent Virologic Response Issues
by: Sundus Bukhari, et al.
Published: (2025-10-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

Impact of Sofosbuvir Plus Daclatasvir Therapy on the Frequency of CD200R<sup>+</sup> Dendritic Cells in Chronic Hepatitis C Virus Infection
by: Helal F. Hetta, et al.
Published: (2024-12-01)

Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment
by: Wafaa M. Ezzat, et al.
Published: (2024-01-01)

Decreased in Liver Fibrosis in Patients with HCV/HIV Coinfection After Treatment with Sofosbuvir/Daclatasvir
by: Andreas Jonathan, et al.
Published: (2020-07-01)

The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis
by: Sidi Mohamed Mah, et al.
Published: (2025-09-01)

Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice
by: Mayadah M. Abdelsalam, et al.
Published: (2023-03-01)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
by: Noha Anwar Hassuna, et al.
Published: (2022-12-01)

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience
by: Tang Q, et al.
Published: (2021-06-01)

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
by: Y. O. SHULPEKOVA, et al.
Published: (2017-05-01)

The effect of psyllium on fasting blood sugar, HbA1c, HOMA IR, and insulin control: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
by: Zeinab Gholami, et al.
Published: (2024-06-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

The association between insulin resistance and risk of developing depression and anxiety disorders in a sample of Egyptian population
by: Hadya Elsayed Abdelfattah, et al.
Published: (2025-04-01)

Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study
by: Kaili Wang, et al.
Published: (2025-07-01)

Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis
by: Ahmed N. Farrag, et al.
Published: (2024-11-01)

The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV
by: Mohamed AbdElrahman, et al.
Published: (2023-01-01)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
by: Hyun Woong Lee, et al.
Published: (2017-09-01)

Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
by: Tyng-Yuan Jang, et al.
Published: (2025-08-01)

The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy
by: Nawfal R Hussein
Published: (2017-01-01)

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure
by: Christiana Graf, et al.
Published: (2024-03-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
by: Adriano Pellicelli, et al.
Published: (2020-05-01)

A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs
by: Shana Yi, et al.
Published: (2024-09-01)

<i>Interleukin 28B</i> Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients
by: Seham Mahrous Zaki, et al.
Published: (2022-09-01)

Relationship of Plasma Gremlin 1 Levels with Body Adiposity and Glycemic Control in Saudi Female Type 2 Diabetes Patients
by: Al-Regaiey KA, et al.
Published: (2022-11-01)

Treatment of hepatitis C virus infection in the future
by: Tatsuo Kanda, et al.
Published: (2013-12-01)

Cardiac effects of direct anti-viral treatment in type II diabetic patients with hepatitis C infection
by: Khaled M. Elmaghraby, et al.
Published: (2024-07-01)

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China
by: Rui Hua, et al.
Published: (2023-10-01)

Adipose tissue IL-23 is associated with fasting blood glucose and HbA1c in overweight/obese individuals
by: Shihab Kochumon, et al.
Published: (2025-10-01)

The Effect of High-Intensity Power Training on Habitual, Intervention and Total Physical Activity Levels in Older Adults with Type 2 Diabetes: Secondary Outcomes of the GREAT2DO Randomized Controlled Trial
by: Marjan Mosalman Haghighi, et al.
Published: (2021-02-01)

Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study
by: Elena B. Romanova, et al.
Published: (2017-12-01)

Avances en hepatitis C
by: Ezequiel Mauro, et al.
Published: (2025-03-01)

Factores preoperatorios correlacionados con la pérdida de peso post-cirugía bariátrica
by: M.A.M. Stumpf, et al.
Published: (2022-10-01)

The impact of a culturally adapted lifestyle intervention on the glycaemic profile of mothers with GDM one year after delivery – a community-based, cluster randomized trial in Sri Lanka
by: Thamudi D. Sundarapperuma, et al.
Published: (2024-07-01)